Skip to main content

Table 2 Clinical and laboratory findings during follow up

From: Methotrexate therapy impacts on red cell distribution width and its predictive value for cardiovascular events in patients with rheumatoid arthritis

 

CV-Event

P

Yes (n = 23)

No (n = 362)

DAS 28 at follow up, mean (SD)

3,12 (0,93)

2,82 (1,37)

0,252

MCV at follow up, mean (SD)

86,6 (5,97)

87,2 (5,7)

0,533

RDW at follow up, mean (SD)

15,1 (2,2)

14,3 (1,5)

0,130

DMARDs at follow up, n (%)

 Methotrexate

15 (65,2%)

207 (57,2%)

0,451

 Sulfasalazine

0

9 (2,5%)

0,445

 Hydroxychloroquine

2 (8,7%)

27 (7,5%)

0,868

 Leflunomide

3 (13%)

15 (4,1%)

0,050

 Azathioprine

0

6 (1,7%)

0,533

 Glucocorticoids

8 (34,8%)

133 (37,5%)

0,810

 bDMARD

8 (34,8%)

130 (36%)

0,892

  1. Clinical and laboratory findings during follow up associated with CV event, significance level at p level ≤ 0,05 –see legend to Table 1, DAS 28 disease activity score 28, MCV mean corpuscular volume, (b)DMARD (biological) disease modifying antirheumatic drug
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us